Home › Companies › PDS BIOTECHNOLOGY CORP. › 2023-2024

PDS BIOTECHNOLOGY CORP. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PDS BIOTECHNOLOGY CORP.’s Form 8-K, filed June 24, 2024 (Item 5.07 on EDGAR). Page generated November 1, 2026.

10Ballot items
107Asset managers
717Fund votes
June 24, 2024Main meeting date

Results at a glance

Meeting of June 24, 2024: 5 items on PDS BIOTECHNOLOGY CORP.’s Form 8-K, filed June 24, 2024: 2 elected · 3 approved.

Meeting of July 14, 2023: 5 items on PDS BIOTECHNOLOGY CORP.’s Form 8-K, filed July 17, 2023: 2 elected · 3 approved.

Material dissent

Elect Director: Kamil Ali-Jackson 67% of votes cast Elected Director under 80%
Elect Director: Otis Brawley, M.D. 78% of votes cast Elected Director under 80%
2. A proposal to approve an amendment to the Eighth Amended and Restated Certificate of Incorporation 78% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024

Explore PDS BIOTECHNOLOGY CORP. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PDS BIOTECHNOLOGY CORP.

These tallies are PDS BIOTECHNOLOGY CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. PDS BIOTECHNOLOGY CORP. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

PDS BIOTECHNOLOGY CORP. — official shareholder meeting results, meeting held June 24, 2024 (Form 8-K, filed June 24, 2024)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Frank Bedu-Addo, Ph.D.	6,718,008	--	--	1,506,996	12,556,503	82%	Elected	—
Elect Director: Otis Brawley, M.D.	6,417,459	--	--	1,807,545	12,556,503	78%	Elected	—
2. A proposal to approve an amendment to the Eighth Amended and Restated Certificate of Incorporation	15,482,514	4,285,087	1,013,906	--	0	78%	Approved	—
3. A proposal to ratify the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024	20,368,680	302,894	109,933	--	0	99%	Approved	—
4. A proposal to approve, by non-binding advisory vote, the compensation of the Company's named executive officers	5,739,901	1,825,608	659,495	--	12,556,503	76%	Approved	—

Source: PDS BIOTECHNOLOGY CORP., Form 8-K, filed with the SEC on June 24, 2024 — read the filing on EDGAR.

PDS BIOTECHNOLOGY CORP. — official shareholder meeting results, meeting held July 14, 2023 (Form 8-K, filed July 17, 2023)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Kamil Ali-Jackson	5,031,970	--	--	2,456,761	10,074,349	67%	Elected	—
Elect Director: Ilian Iliev	6,084,454	--	--	1,404,277	10,074,349	81%	Elected	—
2. Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan	5,637,614	1,168,731	682,386	--	10,074,349	83%	Approved	—
3. Ratification of Appointment KPMG US LLP	17,211,539	258,820	92,721	--	0	99%	Approved	—
4. Approval, by non-binding advisory vote, of the compensation of the Company's named executive officers	6,028,776	1,416,446	43,509	--	10,074,349	81%	Approved	—

Source: PDS BIOTECHNOLOGY CORP., Form 8-K, filed with the SEC on July 17, 2023 — read the filing on EDGAR.

How asset managers voted at the PDS BIOTECHNOLOGY CORP. 2023-2024 meetings

Each item below shows how the 107 asset managers that disclosed a PDS BIOTECHNOLOGY CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Frank Bedu-Addo, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Meeting held June 24, 2024.

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD

FOR: 6,718,008WITHHELD: 1,506,996

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Frank Bedu-Addo, Ph.D.

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“Elect Director: Frank Bedu-Addo, Ph.D.”): 6,718,008 for, 1,506,996 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class C directors until the 2027 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 631,211 for, 30,393 withheld, 6,662 abstained.

FOR

FOR: 631,211ABSTAIN: 6,662WITHHOLD: 30,393

Largest asset managers voting on “Election of Directors: Frank Bedu-Addo, Ph.D.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	270,283	0	0	For
BlackRock	190,052	0	0	For
Global X	51,576	0	0	For
Equitable	42,968	0	0	For
Lincoln Financial	23,500	0	0	For
AIG/SunAmerica	0	0	11,587	Withhold
Northern Trust	10,721	0	0	For
Pacific Life	8,633	0	0	For
Fidelity	8,523	0	0	For
John Hancock	0	6,662	0	Abstain
Principal Exchange-Traded Funds	0	0	5,344	Withhold
Bridge Builder Trust	4,848	0	0	For
TIAA	4,831	0	0	For
Charles Schwab	3,903	0	0	For
Invesco	3,863	0	0	For
Voya	0	0	3,605	Withhold
Principal	0	0	3,271	Withhold
Calvert	0	0	2,309	Withhold
State Street	2,000	0	0	For
T. Rowe Price	1,731	0	0	For
ProShares	0	0	1,571	Withhold
Blackstone Alternative Investment Funds	0	0	1,100	Withhold
PENN SERIES FUNDS INC	1,100	0	0	For
Dimensional	0	0	1,055	Withhold
Morgan Stanley	1,007	0	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

2. Elect Director: Otis Brawley, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Meeting held June 24, 2024.

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD

FOR: 6,417,459WITHHELD: 1,807,545

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Otis Brawley, M.D.

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“Elect Director: Otis Brawley, M.D.”): 6,417,459 for, 1,807,545 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class C directors until the 2027 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 554,203 for, 107,401 withheld, 6,662 abstained.

FORWITHHOLD

FOR: 554,203ABSTAIN: 6,662WITHHOLD: 107,401

Largest asset managers voting on “Election of Directors: Otis Brawley, M.D.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	270,283	0	0	For
BlackRock	190,052	0	0	For
Global X	51,576	0	0	For
Equitable	5,128	0	37,840	Mixed
Lincoln Financial	0	0	23,500	Withhold
AIG/SunAmerica	0	0	11,587	Withhold
Northern Trust	0	0	10,721	Withhold
Pacific Life	8,633	0	0	For
Fidelity	8,523	0	0	For
John Hancock	0	6,662	0	Abstain
Principal Exchange-Traded Funds	0	0	5,344	Withhold
Bridge Builder Trust	4,848	0	0	For
TIAA	0	0	4,831	Withhold
Charles Schwab	3,903	0	0	For
Invesco	3,863	0	0	For
Voya	3,605	0	0	For
Principal	0	0	3,271	Withhold
Calvert	0	0	2,309	Withhold
State Street	0	0	2,000	Withhold
T. Rowe Price	1,731	0	0	For
ProShares	0	0	1,571	Withhold
Blackstone Alternative Investment Funds	0	0	1,100	Withhold
PENN SERIES FUNDS INC	0	0	1,100	Withhold
Dimensional	0	0	1,055	Withhold
Morgan Stanley	1,007	0	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

3. Elect Director: Ilian Iliev

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Meeting held July 14, 2023.

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD

FOR: 6,084,454WITHHELD: 1,404,277

Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: Election of Directors: Ilian Iliev, Ph.D.

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“Elect Director: Ilian Iliev”): 6,084,454 for, 1,404,277 withheld, per its Form 8-K filed July 17, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class B directors until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 971,253 for, 8,993 withheld.

FOR

FOR: 971,253WITHHOLD: 8,993

Largest asset managers voting on “Election of Directors: Ilian Iliev, Ph.D.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	624,929	0	For
Fidelity	236,756	0	For
BlackRock	58,168	0	For
ALPS ETF Trust	18,910	0	For
Charles Schwab	13,278	0	For
Dimensional	0	8,993	Withhold
Blackstone Alternative Investment Funds	7,400	0	For
Equitable	4,391	0	For
Invesco	3,864	0	For
Victory Capital	1,737	0	For
American Century	1,102	0	For
John Hancock	567	0	For
WILSHIRE MUTUAL FUNDS INC	151	0	For

4. Elect Director: Kamil Ali-Jackson

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Meeting held July 14, 2023.

Combines 2 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD

FOR: 5,031,970WITHHELD: 2,456,761

Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: Election of Directors: Kamil Ali-Jackson, Esq.

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“Elect Director: Kamil Ali-Jackson”): 5,031,970 for, 2,456,761 withheld, per its Form 8-K filed July 17, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class B directors until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 700,917 for, 278,762 withheld, 567 abstained.

FORWITHHOLD

FOR: 700,917ABSTAIN: 567WITHHOLD: 278,762

Largest asset managers voting on “Election of Directors: Kamil Ali-Jackson, Esq.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	624,929	0	0	For
Fidelity	0	0	236,756	Withhold
BlackRock	58,168	0	0	For
ALPS ETF Trust	0	0	18,910	Withhold
Charles Schwab	13,278	0	0	For
Dimensional	0	0	8,993	Withhold
Blackstone Alternative Investment Funds	0	0	7,400	Withhold
Equitable	4,391	0	0	For
Invesco	0	0	3,864	Withhold
Victory Capital	0	0	1,737	Withhold
American Century	0	0	1,102	Withhold
John Hancock	0	567	0	Abstain
WILSHIRE MUTUAL FUNDS INC	151	0	0	For

5. 2. A proposal to approve an amendment to the Eighth Amended and Restated Certificate of Incorporation

Official resultCAPITAL STRUCTUREReported outcome: Approved

Meeting held June 24, 2024.

Combines 3 wordings of this item as funds reported it.

78% Approved · of votes cast

FOR 78%AGAINST

FOR: 15,482,514AGAINST: 4,285,087

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To approve an amendment to our Eighth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 75,000,000 shares to 150,000,000 shares;

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“2. A proposal to approve an amendment to the Eighth Amended and Restated Certificate of Incorporation”): 15,482,514 for, 4,285,087 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve the amendment to the Eighth Amended and Restated Certificate of Incorporation.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 611,827 for, 56,439 against.

FOR

FOR: 611,827AGAINST: 56,439

Largest asset managers voting on “To approve an amendment to our Eighth Amended and Restated Certificate of Incorporation, as amended, to increa” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	270,283	0	For
BlackRock	190,052	0	For
Global X	0	51,576	Against
Equitable	42,968	0	For
Lincoln Financial	23,500	0	For
AIG/SunAmerica	11,587	0	For
Northern Trust	10,721	0	For
Pacific Life	8,633	0	For
Fidelity	8,523	0	For
John Hancock	6,662	0	For
Principal Exchange-Traded Funds	5,344	0	For
Bridge Builder Trust	4,848	0	For
TIAA	4,831	0	For
Charles Schwab	0	3,903	Against
Invesco	3,863	0	For
Voya	3,605	0	For
Principal	3,271	0	For
Calvert	2,309	0	For
State Street	2,000	0	For
T. Rowe Price	1,731	0	For
ProShares	1,571	0	For
Blackstone Alternative Investment Funds	1,100	0	For
PENN SERIES FUNDS INC	1,100	0	For
Dimensional	1,055	0	For
Morgan Stanley	1,007	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

6. 2. Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Meeting held July 14, 2023.

Combines 3 wordings of this item as funds reported it.

83% Approved · of votes cast

FOR 83%AGAINST

FOR: 5,637,614AGAINST: 1,168,731

Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: To approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was approved by our Board of Directors on May 19, 2023

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“2. Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan”): 5,637,614 for, 1,168,731 against — passed, per its Form 8-K filed July 17, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 738,524 for, 241,722 against.

FORAGAINST

FOR: 738,524AGAINST: 241,722

Largest asset managers voting on “To approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was ” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	624,929	0	For
Fidelity	0	236,756	Against
BlackRock	58,168	0	For
ALPS ETF Trust	18,910	0	For
Charles Schwab	13,278	0	For
Dimensional	8,993	0	For
Blackstone Alternative Investment Funds	7,400	0	For
Equitable	4,391	0	For
Invesco	0	3,864	Against
Victory Capital	1,737	0	For
American Century	0	1,102	Against
John Hancock	567	0	For
WILSHIRE MUTUAL FUNDS INC	151	0	For

7. 4. A proposal to approve, by non-binding advisory vote, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Meeting held June 24, 2024.

Combines 6 wordings of this item as funds reported it.

76% Approved · of votes cast

FOR 76%AGAINST

FOR: 5,739,901AGAINST: 1,825,608

Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: To approve, by non-binding, advisory vote, the compensation of our named executive officers.

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“4. A proposal to approve, by non-binding advisory vote, the compensation of the Company's named executive officers”): 5,739,901 for, 1,825,608 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 34 asset managers voting on “To approve, by non-binding, advisory vote, the compensation of our named executive officers.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	270,283	0	For
BlackRock	190,052	0	For
Global X	0	51,576	Against
Equitable	42,968	0	For
Lincoln Financial	23,500	0	For
AIG/SunAmerica	11,587	0	For
Northern Trust	10,721	0	For
Pacific Life	8,633	0	For
Fidelity	8,523	0	For
John Hancock	6,662	0	For
Principal Exchange-Traded Funds	5,344	0	For
Bridge Builder Trust	4,848	0	For
TIAA	4,831	0	For
Charles Schwab	3,903	0	For
Invesco	0	3,863	Against
Voya	3,605	0	For
Principal	3,271	0	For
Calvert	0	2,309	Against
State Street	2,000	0	For
T. Rowe Price	1,731	0	For
ProShares	1,571	0	For
Blackstone Alternative Investment Funds	1,100	0	For
PENN SERIES FUNDS INC	1,100	0	For
Dimensional	0	1,055	Against
Morgan Stanley	1,007	0	For

Fund voting reports, all 34 managers: 608,503 for, 59,763 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 67 asset managers voting on “To approve, by non-binding, advisory vote, the compensation of our named executive officers.” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Abstain	Vote
State Street	310,347	0	0	For
Sofinnova Investments, Inc.	142,635	0	0	For
BlackRock	139,053	0	0	For
Northern Trust	113,798	0	0	For
PNC BANK, NATIONAL ASSOCIATION	0	100,008	0	Against
MELLON INVESTMENTS Corp	42,137	0	0	For
AllianceBernstein	37,840	0	0	For
ROCKEFELLER FINANCIAL LLC	26,567	0	0	For
Citadel	25,408	0	0	For
T. Rowe Price	17,539	0	0	For
Invesco	0	15,220	0	Against
Vanguard	13,068	0	0	For
Rhumbline	10,998	0	0	For
JPMorgan	10,963	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	9,812	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	9,724	0	0	For
Goldman Sachs	9,429	0	0	For
PRINCIPAL GLOBAL INVESTORS	8,615	0	0	For
Dimensional	0	8,229	0	Against
DAVENPORT & Co LLC	0	8,000	0	Against
Two Sigma	7,830	0	0	For
Kathleen S. Wright Associates Inc.	0	0	7,000	Abstain
John Hancock	6,734	0	0	For
AQR	6,601	0	0	For
BANK OF AMERICA NA	0	6,122	0	Against

Institutional-manager reports, all 67 managers: 988,487 for, 159,190 against, 7,000 abstained. Showing the 25 largest; see all in the interactive database.

8. 4. Approval, by non-binding advisory vote, of the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Meeting held July 14, 2023.

Combines 3 wordings of this item as funds reported it.

81% Approved · of votes cast

FOR 81%AGAINST

FOR: 6,028,776AGAINST: 1,416,446

Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: To approve, by non-binding, advisory vote, the compensation of our named executive officers

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“4. Approval, by non-binding advisory vote, of the compensation of the Company's named executive officers”): 6,028,776 for, 1,416,446 against — passed, per its Form 8-K filed July 17, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 13 asset managers voting on “To approve, by non-binding, advisory vote, the compensation of our named executive officers” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	624,929	0	For
Fidelity	236,756	0	For
BlackRock	58,168	0	For
ALPS ETF Trust	18,910	0	For
Charles Schwab	13,278	0	For
Dimensional	8,993	0	For
Blackstone Alternative Investment Funds	7,400	0	For
Equitable	4,391	0	For
Invesco	0	3,864	Against
Victory Capital	1,737	0	For
American Century	1,102	0	For
John Hancock	567	0	For
WILSHIRE MUTUAL FUNDS INC	151	0	For

Fund voting reports, all 13 managers: 976,382 for, 3,864 against.

Institutional-manager reports: 39 asset managers voting on “To approve, by non-binding, advisory vote, the compensation of our named executive officers” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Vote
Two Sigma	501,098	0	For
BlackRock	374,812	0	For
Sofinnova Investments, Inc.	285,270	0	For
FIRST MANHATTAN CO. LLC.	271,576	0	For
GEODE CAPITAL MANAGEMENT, LLC	253,853	0	For
Renaissance	103,405	0	For
PNC BANK, NATIONAL ASSOCIATION	100,000	0	For
Point72	86,082	0	For
Citadel	84,149	0	For
Connor, Clark & Lunn Investment Management Ltd.	61,106	0	For
State Street	42,610	0	For
MARSHALL WACE, LLP	15,730	0	For
Charles Schwab	13,278	0	For
Vanguard	12,546	0	For
LAZARI CAPITAL MANAGEMENT, INC.	11,000	0	For
Dimensional	9,629	0	For
T. Rowe Price	8,900	0	For
MELLON INVESTMENTS Corp	8,532	0	For
Goldman Sachs	6,734	0	For
ROCKEFELLER FINANCIAL LLC	6,413	0	For
BALYASNY ASSET MANAGEMENT L.P.	5,438	0	For
Invesco	0	3,864	Against
Mill Creek Capital Advisors, LLC	3,500	0	For
US BANK NATIONAL ASSOCIATION	2,084	0	For
MARIETTA INVESTMENT PARTNERS LLC	0	1,750	Against

Institutional-manager reports, all 39 managers: 2,275,854 for, 5,614 against. Showing the 25 largest; see all in the interactive database.

9. 3. A proposal to ratify the appointment of KPMG US LLP as the Company's independent registered public accounting firm…

Official result Fund totals may overlapAUDIT-RELATEDReported outcome: Approved

Meeting held June 24, 2024.

Combines 4 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 20,368,680AGAINST: 302,894

Details: description as filed, official tally, votes by 35 asset managers

Description as filed by funds: To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“3. A proposal to ratify the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 20,368,680 for, 302,894 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 34 asset managers voting on “To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year e” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Vote
Vanguard	270,283	For
BlackRock	190,052	For
Global X	51,576	For
Equitable	42,968	For
Lincoln Financial	23,500	For
AIG/SunAmerica	11,587	For
Northern Trust	10,721	For
Pacific Life	8,633	For
Fidelity	8,523	For
John Hancock	6,662	For
Principal Exchange-Traded Funds	5,344	For
Bridge Builder Trust	4,848	For
TIAA	4,831	For
Charles Schwab	3,903	For
Invesco	3,863	For
Voya	3,605	For
Principal	3,271	For
Calvert	2,309	For
State Street	2,000	For
T. Rowe Price	1,731	For
ProShares	1,571	For
Blackstone Alternative Investment Funds	1,100	For
PENN SERIES FUNDS INC	1,100	For
Dimensional	1,055	For
Morgan Stanley	1,007	For

Fund voting reports, all 34 managers: 668,266 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 1 asset manager voting on “To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year e” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Greenwich Investment Management, Inc.	5,000	5,000	0	0	Mixed

Institutional-manager reports, all 1 managers: 5,000 for, 5,000 against.

10. 3. Ratification of Appointment KPMG US LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Meeting held July 14, 2023.

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 17,211,539AGAINST: 258,820

Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023

PDS BIOTECHNOLOGY CORP.’s own tally for this item (“3. Ratification of Appointment KPMG US LLP”): 17,211,539 for, 258,820 against — passed, per its Form 8-K filed July 17, 2023 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 980,246 for.

FOR

FOR: 980,246

Largest asset managers voting on “To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year e” at PDS BIOTECHNOLOGY CORP., 2023-2024
Asset manager	For	Vote
Vanguard	624,929	For
Fidelity	236,756	For
BlackRock	58,168	For
ALPS ETF Trust	18,910	For
Charles Schwab	13,278	For
Dimensional	8,993	For
Blackstone Alternative Investment Funds	7,400	For
Equitable	4,391	For
Invesco	3,864	For
Victory Capital	1,737	For
American Century	1,102	For
John Hancock	567	For
WILSHIRE MUTUAL FUNDS INC	151	For

Largest PDS BIOTECHNOLOGY CORP. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 36,679,275 shares outstanding at the time of that meeting.

Fund voting reports: top PDS BIOTECHNOLOGY CORP. shareholders by shares voted on “To approve, by non-binding, advisory vote, the compensation of our named executive officers.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	0.74%
2	BlackRock	0.52%
3	Global X	0.14%
4	Equitable	0.12%
5	Lincoln Financial	0.06%
6	AIG/SunAmerica	0.03%
7	Northern Trust	0.03%
8	Pacific Life	0.02%
9	Fidelity	0.02%
10	John Hancock	0.02%

Institutional-manager reports: top PDS BIOTECHNOLOGY CORP. shareholders by shares voted on “To approve, by non-binding, advisory vote, the compensation of our named executive officers.”, 2023-2024
#	Asset manager	% of shares outstanding
1	State Street	0.85%
2	Sofinnova Investments, Inc.	0.39%
3	BlackRock	0.38%
4	Northern Trust	0.31%
5	PNC BANK, NATIONAL ASSOCIATION	0.27%
6	MELLON INVESTMENTS Corp	0.11%
7	AllianceBernstein	0.10%
8	ROCKEFELLER FINANCIAL LLC	0.07%
9	Citadel	0.07%
10	T. Rowe Price	0.05%

Reported PDS BIOTECHNOLOGY CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PDS BIOTECHNOLOGY CORP. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	5.18%	13F
Geode Capital	1.78%	13F
State Street	1.52%	13F
BlackRock	1.41%	13F
Renaissance Technologies	0.97%	13F
Northern Trust	0.66%	13F
Citadel Advisors	0.36%	13F
Nuveen	0.30%	13F
BNY Mellon	0.27%	13F
Charles Schwab	0.21%	13F

Percentages above are of 36,679,275 shares outstanding, as reported by PDS BIOTECHNOLOGY CORP. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PDS BIOTECHNOLOGY CORP.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At PDS BIOTECHNOLOGY CORP.'s 2 shareholder meetings in the 2023-2024 proxy season (held July 14, 2023 and June 24, 2024), 107 asset managers reported how they voted on 10 ballot items in their SEC Form N-PX filings, covering 717 separate fund positions. On the most widely held item of the season, voted at the meeting held June 24, 2024 — To approve, by non-binding, advisory vote, the compensation of our named executive officers. — PDS BIOTECHNOLOGY CORP.'s filing reports the proposal as approved, with 76% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PDS BIOTECHNOLOGY CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2024.

PDS BIOTECHNOLOGY CORP. proxy season coverage: 2023-2024 (this page).

Download data (CSV): ballot items · votes by manager · column guide.